Vicor Technologies, Inc. Chief Medical Officer Addresses Meeting of the Royal Melbourne Hospital Cardiologists

March 24, 2011 |

5 min read

BOCA RATON, FL--(Marketwire - March 24, 2011) - David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT), today announced that Daniel N. Weiss, MD, FACC, Vicor’s Chief Medical Officer, addressed a meeting of The Royal Melbourne Hospital cardiologists. Vicor Technologies is a biotechnology company focused on the commercialization of its PD2i Analyzer™, an innovative, non-invasive diagnostic employing its patented, proprietary PD2i® nonlinear algorithm. The PD2i Analyzer™ enables physicians to accurately risk stratify specific target populations for future pathological events, including diabetics for the presence of diabetic autonomic neuropathy (DAN), cardiovascular disease patients for death resulting from arrhythmia or congestive heart failure, and trauma victims for imminent death absent immediate lifesaving intervention.

During the meeting, which 30 of The Hospital’s cardiologists attended, Dr. Weiss introduced Vicor’s patented, proprietary PD2i® nonlinear algorithm, described how the PD2i Analyzer™ is being used by cardiologists to measure heart rate variability to assess autonomic nervous system function as a means of identifying the potential for a pathological cardiac event, and discussed the results of recent clinical trials involving the PD2i® nonlinear algorithm.

“We’re grateful to Dr. Harry Mond -- a globally-recognized authority in the cardiac care arena -- for inviting Dr. Weiss to present at one of The Hospital’s weekly cardiology staff meetings. We’re also gratified by the response to Dr. Weiss’ presentation, which included questions about availability of the PD2i Analyzer™ for clinical use in Australia and research opportunities. The response of The Royal Melbourne Hospital cardiologists confirms our understanding that cardiologists worldwide are keenly interested in a non-invasive diagnostic that will enable them to accurately risk stratify patients for future pathological cardiac events,” stated Mr. Fater.

Vicor has a signed agreement with Greatest Asset Limited to serve as its non-exclusive agent for the marketing and sale of its PD2i Analyzer™ in Australia.

About Daniel N. Weiss, MD, FACC
Dr. Weiss has extensive experience in the practice of cardiology and electrophysiology. In addition to serving as Vicor’s chief medical officer, Dr. Weiss is the director of the Jim Moran Heart and Vascular Center at Holy Cross Hospital in Fort Lauderdale. He is also a partner with Florida Arrhythmia Consultants, and has served as a consultant to Fortune 500 medical device manufacturers such as Medtronics, St. Jude Medical, and Guidant. He also served as a clinical investigator on the two most important clinical trials involving the study of ICDs and SCD (MADIT-II (MultiCenter Automatic Defibrillator Implantation Trial) and SCD HeFT (Sudden Cardiac Death Heart Failure Trial). Dr. Weiss earned his MD (with Distinction in Research) from Mount Sinai School of Medicine, from which he also received the Nathan A. Setz Award for Research in Cardiovascular and Renal Disease. He holds a BSE, cum laude, in Electrical Engineering and Computer Science from Princeton University.

About Vicor Technologies, Inc.
Vicor Technologies’ PD2i Analyzer™ employs its patented, proprietary point correlation dimension algorithm (PD2i®), a deterministic, nonlinear measure of electrophysiological potentials that predicts future pathological events with a high degree of accuracy in target populations. The PD2i Analyzer™, which has FDA 510(k) marketing clearance, measures heart rate variability with an easy-to-interpret binary score; physicians performing diagnostic tests with the PD2i Analyzer™ are able to receive reimbursement under existing CPT codes. Vicor anticipates use of its PD2i Analyzer™ to enable early detection and risk stratification for a variety of other disorders and diseases. Additional information is available at www.vicortech.com.

Disclaimer

The appearance of name-brand institutions, such as The Royal Melbourne Hospital and Greatest Asset Limited, in this media release does not constitute endorsement by institutions of the information, products or services contained therein.

Caution Regarding Forward-Looking Statements

Forward-looking statements in this press release are based on current plans and expectations that are subject to uncertainties and risks, which could cause our future results to differ materially. The following factors, among others, could cause our actual results to differ: our ability to successfully complete the normal range study for PD2i® values; our ability to generate revenues from the sale of the PD2i Analyzer™; our ability to obtain the necessary regulatory approvals to market the PD2i Analyzer™; our ability to develop additional applications for the PD2i Analyzer™; our ability to continue to receive financing sufficient to continue operations and complete critical clinical trials; our ability to continue as a going concern; our ability to successfully develop products based on our technologies; our ability to obtain and maintain adequate levels of third-party reimbursement for our products; the impact of competitive products and pricing; our ability to receive regulatory approval for our products; the ability of third-party contract research organizations to perform preclinical testing and clinical trials for our technologies; the ability of third-party manufacturers to manufacture our products; our ability to retain the services of our key personnel; our ability to market and sell our products successfully; our ability to protect our intellectual property; product liability; changes in federal income tax laws and regulations; general market conditions in the medical device and pharmaceutical industries; and other matters that are described in Vicor’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and subsequent filings with the Securities and Exchange Commission. Forward-looking statements in this press release speak only as of the date of the press release, and we assume no obligation to update forward-looking statements or the reasons why actual results could differ.

Release 11-10